New on Science Exchange: VR Tech, Cancer Genetics, Stem Cell-based Organoids

October 26, 2017 | Posted by Team in Innovation Highlight, New Innovations |

Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange |

Nanome Virtual Reality

Virtual Reality Software: Explore biology at nanoscale

From “Fantastic Voyage” (1966) to “A Wind in the Door” (1973), fiction has adored the idea of exploring the body at cellular and molecular levels. Now, virtual reality (VR) software, combined with the computational power afforded by blockchain technology, makes such journeys possible.

For your next computer-aided drug discovery/development (CADD) project, especially if you are collaborating with researchers across multiple sites, try molecular visualization using VR technology — now available from Nanome through Science Exchange.

Visit the Nanome storefront to connect with their team!


Cancer Genetics: Connect patients to discoveries

It’s a great day for precision medicine, with the unveiling of the first global directory of patient-derived xenografts (PDX).

Despite the attention given to precision medicine, however, less than 5% of cancer patients are participating in clinical trials. In the discovery phases of R&D, obtaining biospecimens of specific genotypes is also a continuing challenge.

Oncologists on Science Exchange can now accelerate their research with Cancer Genetics, Inc., a global CRO with a history of thought leadership in precision medicine.

Start a project today with Cancer Genetics, Inc.


Stem Cell-based 3D Organoids: Predict Preclinical Efficacy and Toxicity

3Dnamics Organoid Hippocampus

Organoids, particularly brain organoids, have enabled breakthrough research in Alzheimer’s disease, glioblastoma, and even ZIKA virus-induced microcephaly. By using pluripotent stem cells as a source of the multiple cell types present in an organoid, preclinical researchers can recapitulate in vivo-like tissue architecture and cellular heterogeneity.

Many of these discoveries were made by the founders of 3Dnamics, a new service provider on the Science Exchange network. The 3Dnamics team was built by stem cell pioneers and neuroscientists at Johns Hopkins University School of Medicine. If you are in the process of developing a model system for your preclinical or discovery-phase research, take advantage of 3Dnamics’ expertise.

Visit the 3Dnamics storefront


Guest post: It’s an exciting time to be studying human genetics

March 29, 2012 | Posted by Guest in Innovation Highlight |

This is a guest post by Mark Kaganovich, PhD candidate in Genetics at Stanford University and Founder of SolveBio (full bio below). 

It’s an exciting time to be studying human genetics.  Advances in genomic technologies mean that we are rapidly accumulating information about the genetic differences between individuals and across populations. But, how do those differences in A’s, C’s, T’s and G’s become the differences we see in physical traits or susceptibility to disease? The more we learn about modifications and regulation of DNA, RNA and proteins, the more complicated this question is to answer.

I am a doctoral student at Stanford University – I approach the study of genetic variation by integrating computational data analysis with experimental genomics. Essentially, that means we look across genomes, transcriptomes, and proteomes for patterns in the data, form hypotheses about what those patterns might mean functionally for a cell – and ultimately an organism – and then set out to test those hypotheses. The advent of technologies that generate large, informative data sets and the computational infrastructure to learn from the data means that we can generate meaningful hypotheses quickly. The pace of research depends on our ability to test our hunches and move forward to better understand the cellular mechanisms underlying our genomic/proteomic observations.

Setting up high-throughput experiments to confirm or reject computational predictions usually requires specialized equipment and expertise in scaling up individual experiments that no single laboratory can be expected to afford or master in a reasonable time frame.  So for us, collaboration is a natural avenue to explore. We have looked at working with core facilities and companies to do cell culture, microarray work, and sequencing when in-house lab or core facility capacity and scale cannot meet our needs. There are also methods that we are well set up to perform, but often need results sooner rather than later, so a company or core facility can help.

Read the rest of this entry »

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By